| human | Q5 |
| P496 | ORCID iD | 0000-0003-4451-9800 |
| P734 | family name | Greenbaum | Q21449978 |
| Greenbaum | Q21449978 | ||
| Greenbaum | Q21449978 | ||
| P735 | given name | Carla | Q5041018 |
| Carla | Q5041018 | ||
| P106 | occupation | researcher | Q1650915 |
| Q54522060 | A SNP in G6PC2 predicts insulin secretion in type 1 diabetes. |
| Q34200419 | A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants |
| Q27334999 | A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history |
| Q46901921 | A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. |
| Q92817613 | Abnormalities in proinsulin processing in islets from individuals with longstanding T1D |
| Q30557549 | Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants |
| Q77435857 | Accumulation of(125)iodine labeled interleukin-2 in the pancreas of NOD mice |
| Q100387833 | Acute Hyperinsulinemia Alters Bone Turnover in Women and Men With Type 1 Diabetes |
| Q36621037 | Acute hyperglycemia impairs IL-6 expression in humans |
| Q36216535 | Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. |
| Q36897077 | Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant |
| Q92626522 | An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes |
| Q57158832 | Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 Diabetes |
| Q93077643 | Analysis of pancreatic beta cell specific CD4+ T cells reveals a predominance of proinsulin specific cells |
| Q45060046 | Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes. |
| Q36632019 | Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial |
| Q45070289 | Assessment of Beta Cell Mass and Function by AIRmax and IVGTT in High Risk Subjects for Type 1 Diabetes |
| Q35431818 | Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development |
| Q42511453 | Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. |
| Q92547043 | Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes |
| Q89531588 | Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals |
| Q81390298 | Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes |
| Q47651074 | Autoimmunity to islet proteins in children diagnosed with new-onset diabetes |
| Q91798879 | Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression |
| Q34384116 | Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes |
| Q33638598 | Avidity-dependent programming of autoreactive T cells in T1D |
| Q64120177 | B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes |
| Q37504134 | B-lymphocyte depletion with rituximab and β-cell function: two-year results |
| Q34051583 | Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium |
| Q95837724 | C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet |
| Q47299422 | C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. |
| Q44937301 | CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope |
| Q39228782 | CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. |
| Q64120222 | Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes |
| Q54095939 | Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. |
| Q37289023 | Changes in autoreactive T cell avidity during type 1 diabetes development. |
| Q28082038 | Changing the Course of Disease in Type 1 Diabetes |
| Q35822130 | Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study |
| Q36292592 | Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial |
| Q42683654 | Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363. |
| Q44914587 | Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects |
| Q45057620 | Conformation-dependent GAD65 autoantibodies in diabetes |
| Q37660900 | Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment |
| Q93222769 | DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes |
| Q33604570 | Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects |
| Q27687598 | Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report |
| Q92924665 | Discriminative T cell recognition of cross-reactive islet-antigens is associated with HLA-DQ8 transdimer-mediated autoimmune diabetes |
| Q28081034 | Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going? |
| Q46443792 | Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr |
| Q90906152 | Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice |
| Q51286634 | Dissecting heterogeneity in paediatric Type 1 diabetes: association of TCF7L2 rs7903146 TT and low-risk human leukocyte antigen (HLA) genotypes. |
| Q92510211 | Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression |
| Q40730821 | Dynamic perifusion to maintain and assess isolated pancreatic islets |
| Q80756038 | Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out |
| Q47375383 | Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial |
| Q36860483 | Effect of rituximab on human in vivo antibody immune responses |
| Q51599003 | Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team. |
| Q46458859 | Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. |
| Q89170907 | Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes |
| Q50077957 | Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes |
| Q41751738 | Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression |
| Q44065091 | Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet. |
| Q64079230 | Erratum. Genetics coming of age in type 1 diabetes. Diabetes Care 2019;42:189-191 |
| Q55069722 | Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787. |
| Q90050493 | Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236 |
| Q43902397 | Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes |
| Q82095901 | Evaluation of leptin levels in subjects at risk for type 1 diabetes |
| Q33751549 | Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes |
| Q39596760 | Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose |
| Q30521476 | Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data |
| Q53393942 | Fifth International Serum Exchange Workshop for Insulin Autoantibody (IAA) Standardization. The Immunology and Diabetes Workshops and participating laboratories |
| Q112293186 | Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes |
| Q58065034 | First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes |
| Q42554128 | Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects |
| Q35718804 | Future intervention trials in type 1 diabetes |
| Q44903844 | GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes |
| Q92023736 | Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC |
| Q44932416 | Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes |
| Q91148217 | Genetics Coming of Age in Type 1 Diabetes |
| Q30505367 | Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). |
| Q44893510 | Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes |
| Q30732418 | HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression |
| Q36749719 | Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective |
| Q90615969 | High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes |
| Q44907145 | High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes |
| Q92374450 | High residual C-peptide likely contributes to glycemic control in type 1 diabetes |
| Q92454501 | Hyaluronan deposition in islets may precede and direct the location of islet immune-cell infiltrates |
| Q91932842 | Hybrid Insulin Peptides are Recognized by Human T Cells in the Context of DRB1*04:01 |
| Q38090144 | IL-2 therapy in type 1 diabetes: "Trials" and tribulations |
| Q90558643 | ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents |
| Q44924300 | Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives |
| Q36770646 | Identification of tissue-specific cell death using methylation patterns of circulating DNA |
| Q82201101 | Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope |
| Q43935399 | Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose |
| Q53392926 | Improved specificity of ICA assays in the Fourth International Immunology of Diabetes Serum Exchange Workshop |
| Q30418470 | Improvement in outcomes of clinical islet transplantation: 1999-2010. |
| Q90307145 | In-vivo assessment of T cell kinetics in individuals at risk for type 1 diabetes |
| Q37319146 | Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1 |
| Q67558235 | Increased specificity and sensitivity of insulin antibody measurements in autoimmune thyroid disease and type I diabetes |
| Q51482531 | Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. |
| Q56871556 | Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes |
| Q96157281 | Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes |
| Q37084340 | Insulin Antibodies and Insulin Autoantibodies |
| Q68101221 | Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of |
| Q98395270 | Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes |
| Q34733637 | Insulin resistance in type 1 diabetes |
| Q34718501 | Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database |
| Q37307777 | Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials |
| Q36788764 | Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset |
| Q43567137 | Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes |
| Q79855751 | International comparison of C-peptide measurements |
| Q34197036 | Intra-islet insulin permits glucose to directly suppress pancreatic A cell function |
| Q91385263 | Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes |
| Q46947522 | Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes |
| Q73555628 | Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1 |
| Q34496667 | Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. |
| Q36271849 | Latent autoimmune diabetes in adults (LADA) should be less latent |
| Q39069291 | Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home |
| Q42242979 | Low HERV-K(C4) copy number is associated with type 1 diabetes |
| Q73558994 | Low serum conditions for in vitro generation of human macrophages with macrophage colony stimulating factor |
| Q57163295 | Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 Diabetes |
| Q92985801 | Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data |
| Q44201166 | Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. |
| Q37360444 | Major histocompatibility complex class I molecule expression is normal on peripheral blood lymphocytes from patients with insulin-dependent diabetes mellitus |
| Q37972677 | Making progress: preserving beta cells in type 1 diabetes |
| Q44995611 | Male sex increases the risk of autoimmunity but not type 1 diabetes |
| Q51075668 | Measurement of Pro-Islet Amyloid Polypeptide (1-48) in Diabetes and Islet Transplants. |
| Q35182110 | Metabolic tests to determine risk for type 1 diabetes in clinical trials |
| Q36906207 | Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes |
| Q52719485 | Modifying Enzymes are Elicited by ER Stress, Generating Epitopes that are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes. |
| Q34393367 | Molecular signatures differentiate immune states in type 1 diabetic families |
| Q35078225 | Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients |
| Q96644719 | Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic beta-cells |
| Q45028780 | NETosis-associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count |
| Q71674503 | Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM |
| Q48956405 | Non-invasive imaging of beta cell mass: a quantitative analysis |
| Q45248639 | Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study |
| Q57159227 | Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study |
| Q34213378 | Parenteral insulin suppresses T cell proliferation to islet antigens |
| Q46966748 | Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. |
| Q41145019 | Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins |
| Q42641842 | Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes |
| Q44930850 | Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression? |
| Q37364982 | Preservation of beta-cell function in autoantibody-positive youth with diabetes |
| Q41676427 | Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes |
| Q30548217 | Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth |
| Q82855435 | Progress, but not yet ready for clinical use: interrupting immune-mediated destruction of pancreatic beta cells in type 1 diabetes |
| Q90366148 | Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes |
| Q58037336 | Prospective evaluation of β-cell function in insulin antoantibody-positive relatives of insulin-dependent diabetic patients |
| Q36182476 | Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function |
| Q39499765 | Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. |
| Q57158691 | Reduced CD11b Integrin Expression with Short-term Administration of an IL-1R Antagonist in Type 1 Diabetes Patients |
| Q58037248 | Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study |
| Q38197230 | Residual C-peptide in type 1 diabetes: what do we really know? |
| Q90213433 | Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258-264 |
| Q97567539 | Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. Diabetes Care 2020;43:913-917 |
| Q42909824 | Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073. |
| Q55185852 | Response to Comment on: Greenbaum et al. Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes. Diabetes 2012;61:1323–1330. |
| Q57491711 | Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function |
| Q80400738 | Role of insulin resistance in predicting progression to type 1 diabetes |
| Q34079225 | Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes |
| Q102056526 | Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR |
| Q57158666 | Short-term IL-1β blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes |
| Q51000341 | Short-term responses to periodontal therapy in insulin-dependent diabetic patients. |
| Q40190431 | Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes. |
| Q82497133 | Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes |
| Q45070795 | Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease. |
| Q37659402 | Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association |
| Q45234917 | Standardization of C-peptide measurements |
| Q88697599 | Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience |
| Q36340392 | Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic Controller |
| Q90401076 | Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal Study |
| Q44748000 | Systematic screening of potential beta-cell imaging agents |
| Q57158739 | T.128. Short-term Administration of Anakinra does not Appear to Affect Stimulated C-peptide Responses Acutely in Patients with Type 1 Diabetes |
| Q37642554 | Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial |
| Q37251153 | Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders |
| Q35531898 | The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance |
| Q53403038 | The Fourth International Workshop on the Standardisation of Insulin Autoantibody Workshop. |
| Q28571629 | The antibody response to bacteriophage is linked to the lymphopenia gene in congenic BioBreeding rats |
| Q36047238 | The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes |
| Q44865704 | The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes |
| Q27334960 | The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months |
| Q37257559 | The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis |
| Q41146074 | The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells |
| Q33817024 | The influence of exposure to maternal diabetes in utero on the rate of decline in β-cell function among youth with diabetes |
| Q37368421 | The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants |
| Q38012381 | Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes |
| Q37327047 | Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years |
| Q90655323 | Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis |
| Q33683763 | Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants |
| Q34055005 | Type 1 Diabetes TrialNet--an international collaborative clinical trials network |
| Q88112314 | Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes |
| Q34775694 | Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials |
| Q37252933 | Type 1 diabetes mellitus: primary, secondary, and tertiary prevention |
| Q43555565 | Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria |
| Q46486153 | Understanding and preventing type 1 diabetes through the unique working model of TrialNet |
| Q33902878 | Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease |
| Q44194569 | Use of a "fuzzy logic" controller in a closed-loop artificial pancreas |
| Q46712450 | Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitus |
| Q30574604 | Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes |
| Q30502785 | Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study |
| Q90316015 | Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention |
| Q35976503 | Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies |
Search more.